October 6, 2009 - At the University of Virginia Health System where they opened a new Magnetic Resonance Guided Focused Ultrasound Surgery Center, specialists are using magnetic resonance guided focused ultrasound (MRgFUS) to perform research that will represent a wide range of disciplines, including anesthesiology, biomedical engineering, gynecology, neurology, neurosurgery, oncology, radiology, radiation oncology surgery and urology.

Within coming months, research will focus on using MRgFUS to treat brain, breast, prostate, bone and liver tumors and conditions such as epilepsy, stroke, chronic pain, Parkinson's disease and essential tremor.

Neal F. Kassell, M.D., a professor of neurosurgery at the University of Virginia's School of Medicine believes that MRgFUS may be the most important therapeutic development since the scalpel.

During MRgFUS treatments, which are noninvasive and performed on an outpatient basis, patients lie on a table while doctors use the visual capabilities of magnetic resonance imaging to direct hundreds of individual and normally harmless sound waves at a single treatment point deep inside the body.

When ultrasound waves intersect the intense energy destroys tumor cells, and according to Alan H. Matsumoto, M.D. and chairman of UVA’s Department of Radiology and co-director of the new center, the technology is so precise that it can treat sites as small as a millimeter.

Treatments, which will become available in late October, will take about three hours. Side effects, if any, are typically minimal - minor cramping is most common - and patients can expect to feel well enough to resume daily activities almost immediately.

James M. Larner, M.D., director of UVA's Focused Ultrasound Center and chairman of the Department of Radiation Oncology, notes that focused ultrasound has the ability to destroy 100 percent of cancer cells, unlike chemotherapy, which kills only a certain percentage of malignant cells. Also, cancer cells cannot become resistant to focused ultrasound in contrast to chemotherapy. In addition, focused ultrasound has a rapid dosing drop off, meaning the technology concentrates high levels of heat on a target site but does not spill over to nearby healthy tissue, potentially causing damage or patient complications.

For more information: www.virginia.edu


Related Content

News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Radiology Imaging

March 23, 2026 — Samsung Medison hsa announced that its U.S. medical imaging businesses, previously operating as ...

Time March 23, 2026
arrow
News | MRI Breast | Breast cancer, dense breast, MRI

March 2, 2026 — A collaborative modeling study found that adding biennial breast magnetic resonance imaging (MRI) to ...

Time March 20, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | HIMSS

March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...

Time March 06, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Women's Health

March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...

Time March 03, 2026
arrow
Subscribe Now